Candel Therapeutics (NASDAQ:CADL) Given New $18.00 Price Target at HC Wainwright

Key Points

• HC Wainwright cut its price target on Candel Therapeutics to $18 from $23 but maintained a Buy rating; the new target implies 183.46% upside from the stock’s reported $6.35 price.
• Analyst views are mixed: nine analysts rate the shares Buy and two Sell, for a consensus Moderate Buy and average target of $18.57. Other firms have also lowered targets, including Canaccord Genuity, which cut its target to $13 while keeping a Buy rating.
• Candel reported a quarterly loss of $0.28 per share, narrower than analysts’ expected loss of $0.34. The stock fell $2.04 on Friday to $6.35.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) had its target price reduced by investment analysts at HC Wainwright from $23.00 to $18.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 183.46% from the stock's current price.

A number of other brokerages have also recently weighed in on CADL. Bank of America upgraded shares of Candel Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $12.00 to $18.00 in a research note on Monday, September 21st. Zacks Research lowered shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday, October 14th. UBS Group reiterated a "buy" rating on shares of Candel Therapeutics in a report on Monday, August 17th. Canaccord Genuity Group cut their price target on Candel Therapeutics from $25.00 to $13.00 and set a "buy" rating for the company in a report on Friday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $18.57.

Candel Therapeutics Stock Performance

Shares of CADL stock traded down $2.04 during trading on Friday, reaching $6.35. The company had a trading volume of 4,194,395 shares, compared to its average volume of 1,438,046. The firm's 50 day simple moving average is $9.89 and its two-hundred day simple moving average is $8.39. Candel Therapeutics has a one year low of $4.35 and a one year high of $14.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. The company has a market capitalization of $485.90 million, a PE ratio of -4.49 and a beta of -0.27.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. Sell-side analysts forecast that Candel Therapeutics will post -1.29 earnings per share for the current year.

Insiders Place Their Bets

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the sale, the chief technology officer owned 76,865 shares of the company's stock, valued at $922,380. The trade was a 8.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 14.30% of the stock is owned by corporate insiders.

Institutional Trading of Candel Therapeutics

Institutional investors have recently made changes to their positions in the business. AlphaCentric Advisors LLC raised its position in Candel Therapeutics by 4.3% in the third quarter. AlphaCentric Advisors LLC now owns 38,259 shares of the company's stock worth $399,000 after purchasing an additional 1,576 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Candel Therapeutics by 19.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company's stock valued at $152,000 after purchasing an additional 2,301 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of Candel Therapeutics by 12.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company's stock valued at $149,000 after purchasing an additional 3,400 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Candel Therapeutics in the 3rd quarter worth approximately $41,000. Finally, Profund Advisors LLC raised its holdings in shares of Candel Therapeutics by 16.1% in the 3rd quarter. Profund Advisors LLC now owns 33,301 shares of the company's stock worth $348,000 after buying an additional 4,624 shares in the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Recent Candel Therapeutics Headlines

Investors following CADL have been watching these headlines:

• Positive Sentiment: Candel reported a third-quarter loss of $0.28 per share, narrower than analysts’ $0.34-per-share estimate. Candel Therapeutics Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Canaccord Genuity and Stifel Nicolaus kept Buy ratings but cut their price targets to $13 and $19, respectively, from $25 and $22. The retained ratings are supportive, while the lower targets reflect more cautious expectations. Canaccord Genuity price-target update Stifel Nicolaus price-target update
• Negative Sentiment: Candel now expects to submit a Biologics License Application for aglatimagene around mid-2027. The later timeline delays a key regulatory milestone and adds uncertainty about when the therapy could reach the market, weighing on the shares. Candel outlines mid-2027 BLA plan

Candel Therapeutics Company Profile

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.